GSK Integrates Oncology R&D

GlaxoSmithKline has formed GSK Oncology, a newly integrated Oncology R&D Organization. GSK Oncology unites small discovery units (DPUs) within the existing Centre of Excellence for Drug Discovery (CEDD), and a highly specialized drug development group to create a dedicated oncology R&D organization, led by Paolo Paoletti, M.D., senior vice president Oncology R&D.

“GSK has designed this new organization to help us increase the breadth and depth of our core oncology knowledge, in order to ultimately deliver more innovative medicines that enhance cancer patients’ lives,” said Dr. Paoletti. “By creating an end-to-end R&D unit we are able to capture the many synergies that exist between discovery and development in oncology. The application of translational medicine will bring about significant enhancements to the R&D group via the ‘bench to bed’ connection — the constant loop and flow of information from early to late stage development, and vice-versa.”

“The newly formed GSK R&D Oncology Unit is directly aligned with our R&D strategy to deliver more products of value, and will help us increase our efforts towards personalized medicine in oncology,” said Moncef Slaoui, chairman, R&D. “This dedicated unit will have the primary goals of identifying new targets and pathways, conducting innovative clinical research and cost-effectively increasing development capacity in order to deliver the unit’s large portfolio of medicines.”